Patent number: 9856216
Abstract: Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.
Type:
Grant
Filed:
April 21, 2016
Date of Patent:
January 2, 2018
Assignee:
GREEN CROSS CORPORATION
Inventors:
Soongyu Choi, Eun-Jung Park, Hee Jeong Seo, Younggyu Kong, Ickhwan Son, Sang-ho Ma, Man-Young Cha, Mi-Soon Kim, Kisoo Park
Publication number: 20170152251
Abstract: The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.
Type:
Application
Filed:
July 18, 2014
Publication date:
June 1, 2017
Applicants:
GREEN CROSS CORPORATION, LEGOCHEM BIOSCIENCES,INC.
Inventors:
Soongyu CHOI, Jungsub CHOI, So-Hyun YOON, Yoo Hoon KIM, Jae Yeon KIM, Suk Ho LEE, Young Lag CHO, Ho Young SONG, Dae Yon LEE, Sung Yoon BAEK, Sang Eun CHAE, Tae Kyo PARK, Sung Ho WOO, Yong Zu KIM
Publication number: 20160311772
Abstract: Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.
Type:
Application
Filed:
April 21, 2016
Publication date:
October 27, 2016
Applicant:
GREEN CROSS CORPORATION
Inventors:
Soongyu CHOI, Eun-Jung PARK, Hee Jeong SEO, Younggyu KONG, Ickhwan SON, Sang-ho MA, Man-Young CHA, Mi-Soon KIM, Kisoo PARK
Publication number: 20160297815
Abstract: Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.
Type:
Application
Filed:
March 24, 2016
Publication date:
October 13, 2016
Applicant:
GREEN CROSS CORPORATION
Inventors:
Soongyu CHOI, Kwang-Seop SONG, Hee Jeong SEO, Sang-ho MA, Eun-Jung PARK, Younggyu KONG, So Ok PARK, Kisoo PARK, Ickhwan SON, Min Ju KIM, Man-Young CHA, Mi-Soon KIM, Sang Mi KANG, Dong Hyuk JANG, Jangwon HONG
Publication number: 20160289196
Abstract: Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.
Type:
Application
Filed:
March 29, 2016
Publication date:
October 6, 2016
Applicant:
GREEN CROSS CORPORATION
Inventors:
Soongyu CHOI, Kisoo PARK, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, Ickhwan SON, Sang-ho MA, Kwang-Seop SONG, Min Ju KIM, So Ok PARK, Man-Young CHA, Mi-Soon KIM, Sang Mi KANG, Dong Hyuk JANG, Jangwon HONG